

## DAFTAR PUSTAKA

1. Perhimpunan Dokter Spesialis Kardiovaskular Indonesia. Pedoman diagnosis dan tatalaksana hipertensi pulmonal. 1 ed. Indonesia; 2021. 1–148.
2. Tyagi R, Kant S, Pradhan A, Wakhlu A, Bajaj DK, Bajpai J. Estimates of Prevalence of Pulmonary Hypertension according to Different International Definitions. *Can Respir J*. 2021;2021:1–8.
3. Yovie K. Buku Ajar Kardiovaskular FKUI. 2 ed. Jakarta: Sagung Seto; 2017. 1–50.
4. Coons JC, Pogue K, Kolodziej AR, Hirsch GA, George MP. Pulmonary arterial hypertension: a pharmacotherapeutic update. *Curr Cardiol Rep*. 2019;21(11):1–12.
5. Nicole F. Ruopp M, Barbara A. Cockrill M. Diagnosis and treatment of pulmonary arterial hypertension a review. *JAMA*. 2022;1–15.
6. Dodson MW, Brown LM, Elliott CG. Pulmonary arterial hypertension. *Heart Fail Clin*. 2018;14(3):1–14.
7. Mandras SA, Mehta HS, Vaidya A. Pulmonary hypertension: a brief guide for clinicians. *Mayo Clin Proc*. 2020;95(9):1–10.
8. Maron BA, Abman SH, Elliott CG, Frantz RP, Hopper RK, Horn EM, et al. Pulmonary arterial hypertension: diagnosis, treatment, and novel advances. *Am J Respir Crit Care Med*. 2021;203(12):1472–87.
9. Levine DJ. Pulmonary arterial hypertension: updates in epidemiology and evaluation of patients. *Am J Manag Care*. 2021;27(3):35–41.
10. Humbert M, Farber HW, Ghofrani HA, Benza RL, Busse D, Meier C, et al. Risk assessment in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. *Eur Respir J*. 2019;53(6):1–16.
11. Xanthouli P, Koegler M, Marra AM, Benjamin N, Fischer L, Eichstaedt CA, et al. Risk stratification and prognostic factors in patients with pulmonary arterial hypertension and comorbidities a cross-sectional cohort study with survival follow-up. *Respir Res*. 2020;21(1):1–11.
12. Frantz RP, Hill JW, Lickert CA, Wade RL, Cole MR, Tsang Y, et al. Medication adherence, hospitalization, and healthcare resource utilization and costs in patients with pulmonary arterial hypertension treated with endothelin receptor antagonists or phosphodiesterase type-5 inhibitors. *Pulm Circ*. 2020;10(1):1–11.
13. Showalter K, Ma X, Pinheiro L, Sobol I, Gordon JK, Mehta B. Thirty-day hospital readmission in systemic sclerosis associated pulmonary hypertension: a nationwide study. *Semin Arthritis Rheum*. 2021;51(1):1–6.
14. Bhattacharya PT, Hameed AMA, Bhattacharya ST, Chirinos JA, Hwang WT, Birati EY, et al. Risk factors for 30-day readmission in adults hospitalized for pulmonary hypertension. *Pulm Circ*. 2020;10(4):1–14.
15. Rajdev A, Garan H, Biviano A. Arrhythmias in pulmonary arterial hypertension. *Prog Cardiovasc Dis*. 2012;55(2):1–10.
16. Naranjo M, Mercurio V, Hassan H, Alturaif N, Cuomo A, Attanasio U, et al. Causes and outcomes of ICU hospitalisations in patients with pulmonary arterial hypertension. *ERJ Open Res*. 2022;8(2):1–11.
17. Sud M, Yu B, Wijesundera HC, Austin PC, Ko DT, Braga J, et al.

- Associations between short or long length of stay and 30-day readmission and mortality in hospitalized patients with heart failure. *JACC Hear Fail.* 2017;5(8):578–88.
18. Cheron C, McBride SA, Antigny F, Girerd B, Chouchana M, Chaumais MC, et al. Sex and gender in pulmonary arterial hypertension. *Eur Respir Rev.* 2021;30(162):1–21.
  19. Deborah Jo Levine, MD F. Pulmonary arterial hypertension: updates in epidemiology and evaluation of patients. *Am J Manag Care.* 2021;27(3):1–15.
  20. Wang XJ, Lian TY, Jiang X, Liu SF, Li SQ, Jiang R, et al. Germline BMP9 mutation causes idiopathic pulmonary arterial hypertension. *Eur Respir J.* 2019;53(3):1–10.
  21. Rosenzweig EB, Abman SH, Adatia I, Beghetti M, Bonnet D, Haworth S, et al. Paediatric pulmonary arterial hypertension: Updates on definition, classification, diagnostics and management. *Eur Respir J.* 2019;53(1):1–18.
  22. Chalmers SJ, Murphy SJ, Thompson LL, Hoppman NL, Smadbeck JB, Balcom JR, et al. Mate-pair sequencing identifies a cryptic BMPR2 mutation in hereditary pulmonary arterial hypertension. *Pulm Circ.* 2020;10(3):1–4.
  23. Ramirez R, Pienkos S, Perez V, Zamanian R. Pulmonary arterial hypertension secondary to drugs and toxins. *Clin Chest Med.* 2021;42(1):19–38.
  24. Vonk MC, Vandecasteele E, van Dijk AP. Pulmonary hypertension in connective tissue diseases, new evidence and challenges. *Eur J Clin Invest.* 2021;51(4):1–12.
  25. Liu Y, Han J, Li B, Xiao J, Zhang L, Zhao H. Risk factors associated with pulmonary arterial hypertension among HIV-infected adults: a meta-analysis and systematic review. *AIDS Rev.* 2022;24(2):1–9.
  26. Knafl D, Gerges C, King CH, Humbert M, Bustinduy AL. Schistosomiasis-associated pulmonary arterial hypertension: a systematic review. *Eur Respir Rev.* 2020;29(155):1–12.
  27. Lefebvre B, Kyheng M, Giodarno J, Lamblin N, Groote P, Fertin M, et al. Dual-energy CT lung perfusion characteristics in pulmonary arterial hypertension (PAH) and pulmonary veno-occlusive disease and/or pulmonary capillary hemangiomatosis (PVOD/PCH): preliminary experience in 63 patients. *Eur Radiol.* 2022;32(7):1–12.
  28. Thenappan T, Ormiston ML, Ryan JJ, Archer SL. Pulmonary arterial hypertension: pathogenesis and clinical management. *BMJ.* 2018;360:1–27.
  29. Zhang Z qiang, Zhu S kui, Wang M, Wang X an, Tong X hong, Wan J qiao, et al. New progress in diagnosis and treatment of pulmonary arterial hypertension. *J Cardiothorac Surg.* 2022;17(1):1–9.
  30. Dinarti L, Anggrahini D, Lilyasari O, Siswanto B, Hartopo A. Pulmonary arterial hypertension in Indonesia: current status and local application of international guidelines. *Glob Heart.* 2021;16(1):1–12.
  31. Callejo M, Barberá JA, Duarte J, Perez-Vizcaino F. Impact of nutrition on pulmonary arterial hypertension. *Nutrients.* 2020;12(1):1–18.
  32. Simonneau G, Montani D, Celermajer DS, Denton CP, Gatzoulis MA, Krowka M, et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. *Eur Respir J.* 2019;53(1):1–13.

33. Ge X, Zhu T, Zhang X, Liu Y, Wang Y, Zhang W. Gender differences in pulmonary arterial hypertension patients with BMPR2 mutation: A meta-analysis. *Respir Res.* 2020;21(1):1–10.
34. Ballard W, Dixon B, McEvoy CA, Verma AK. Pulmonary arterial hypertension in pregnancy. *Cardiol Clin.* 2021;39(1):1–9.
35. Martinez M, Rubledo G, Valadez E, Aldama D, Vergara D, Cesar M, et al. A brief review on gender differences in Mexican-Mestizo patients with pulmonary arterial hypertension (PAH) at a tertiary-level hospital. *Curr Probl Cardiol.* 2022;47(9):1–9.
36. Schiess R, Senn O, Fischler M, Huber L, Vatandaslar S, Speich R, et al. Tobacco smoke: a risk factor for pulmonary arterial hypertension? a case-control study. *Chest.* 2010;138(5):1086–92.
37. Badesch D, Raskob C, Krichman A, Farber H, Frost A, Al E. Pulmonary arterial hypertension: baseline characteristics from the reveal registry. *Chest.* 2010;137(2):376–87.
38. Hartopo AB, Dinarti LK. The shared pathogenesis of pulmonary artery hypertension. *Acta Cardiol Indones.* 2018;4(1):22–7.
39. Rajagopal S, Yu YRA. The pathobiology of pulmonary arterial hypertension. *Cardiol Clin.* 2022;40(1):1–12.
40. Galiè N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, et al. 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. *Eur Respir J.* 2015;46(4):1–72.
41. Task A, Members F, Humbert M, Germany MMH, Berger RMF, Denmark JC, et al. 2022 ESC / ERS Guidelines for the diagnosis and treatment of pulmonary hypertension developed by the task force for the diagnosis and treatment of ( ESC ) and the European Respiratory Society ( ERS ). *Eur Heart J.* 2022;43(38):1–114.
42. Simonneau G, Montani D, Celermajer DS, Denton CP, Gatzoulis MA, Krowka M, et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. *Eur Respir J.* 2021;17(2):1–5.
43. Frost A, Badesch D, Gibbs JS, Gopalan D, Khanna D, Manes A, et al. Diagnosis of pulmonary hypertension. *Eur Respir J.* 2019;53(1):1–12.
44. Yaghi S, Novikov A, Trandafirescu T. Clinical update on pulmonary hypertension. *J Investig Med.* 2020;68(4):821–7.
45. Abu T, Levi A, Hasdai D, Kramer MR, Bental T, Bdolah-Abram T, et al. Preoperative evaluation of pulmonary hypertension in lung transplant candidates: echocardiography versus right heart catheterization. *BMC Cardiovasc Disord.* 2022;22(1):1–7.
46. Vazquez ZGS, Klinger JR. Guidelines for the treatment of pulmonary arterial hypertension. *Lung.* 2020;198(4):581–96.
47. Sadowski M, Janion A, Ketek A, Raczynski G, Zandecki T. Pulmonary arterial hypertension : diagnosis and treatment. *Internist Prax.* 2013;29(3):1–6.
48. Barańska-Pawelczak K, Wojciechowska C, Jacheć W. Diagnostic and predictive value of right heart catheterization-derived measurements in pulmonary hypertension. *Wiad Lek.* 2021;74(3):1–7.
49. Suling FRW. Hipertensi arteri pulmonalis. *Maj Kedokt FK UKI.* 2010;27(4):173–83.

50. Galiè N, Channick RN, Frantz RP, Grünig E, Jing ZC, Moiseeva O, et al. Risk stratification and medical therapy of pulmonary arterial hypertension. *Eur Respir J*. 2019;53(1):1–11.
51. Maron BA, Abman SH, Elliott CG, Frantz RP, Hopper RK, Horn EM, et al. Pulmonary arterial hypertension: diagnosis, treatment, and novel advances. *Am J Respir Crit Care Med*. 2021;203(12):1–15.
52. Hansmann G. Pulmonary hypertension in infants, children, and young adults. *J Am Coll Cardiol*. 2017;69(20):2551–69.
53. Hirakawa K, Aoki T, Tsuji A, Ogo T. Pulmonary arterial hypertension sensitive to calcium channel blocker, but not advanced pulmonary hypertension treatment: a case report. *Eur Hear J - Case Reports*. 2022;6(9):1–4.
54. Liu C, Chen J, Gao Y, Deng B, Liu K. Endothelin receptor antagonists for pulmonary arterial hypertension. *Cochrane Database Syst Rev*. 2021;2021(3):1–89.
55. Klinger J, Elliott C, Levine D, Bossone L, Duvall L, Fargan K, et al. Therapy for pulmonary arterial hypertension in adults: update of the chest guideline and expert panel report. *Chest*. 2019;155(3):20.
56. Cooper AS. Prostacyclin for pulmonary arterial hypertension. *Crit Care Nurse*. 2022;42(2):1–2.
57. Rothbard N, Agrawal A, Fischer C, Talwar A, Sahni S. Pulmonary arterial hypertension in the elderly: clinical perspectives. *Cardiol J*. 2020;27(2):184–93.
58. Jonas K, Kurzyna M, Mroczek E, Chrzanowski Ł, Mularek-Kubzdela T, Skoczylas I, et al. Impact of diabetes mellitus on disease severity and patient survival in idiopathic pulmonary arterial hypertension: data from the Polish Multicentre Registry (BNP-PL). *Cardiovasc Diabetol*. 2023;22(177):1–9.
59. Rhodes CJ, Wharton J, Howard L, Gibbs JSR, Vonk-Noordegraaf A, Wilkins MR. Iron deficiency in pulmonary arterial hypertension: a potential therapeutic target. *Eur Respir J*. 2011;38(6):1453–60.
60. Weatherald J, Huertas A, Boucly A, Guignabert C, Taniguchi Y, Adir Y, et al. Association between BMI and obesity with survival in pulmonary arterial hypertension. *Chest*. 2018;154(4):1–10.
61. Zaya M, Phan A. Predictors of re-hospitalization in patients with chronic heart failure. *World J Cardiol*. 2015;7(10):665–71.
62. Munshi RF, Pellegrini JR, Patel P, Kashin M, Kang J, Sexton R, et al. Impact of pulmonary hypertension in patients with acute exacerbation of chronic obstructive pulmonary disease and its effect on healthcare utilization. *Pulm Circ*. 2021;11(4):1–6.
63. Nickel NP, O’Leary JM, Brittain EL, Fessel JP, Zamanian RT, West JD, et al. Kidney dysfunction in patients with pulmonary arterial hypertension. *Pulm Circ*. 2017;7(1):38–54.
64. Vonk-Noordegraaf A, Haddad F, Chin KM, Forfia PR, Kawut SM, Lumens J, et al. Right heart adaptation to pulmonary arterial hypertension: physiology and pathobiology. *J Am Coll Cardiol*. 2013;62(25):22–33.
65. Hjalmarsson C, Rådegran G, Kylhammar D, Rundqvist B, Multing J, Nisell MD, et al. Impact of age and comorbidity on risk stratification in idiopathic pulmonary arterial hypertension. *Eur Respir J*. 2018;51(5):1–9.

66. Windayanti KA. Hubungan tingkat aktivitas fisik dengan tekanan darah pada pekerja yang bekerja dari rumah selama masa pandemi Covid-19 di wilayah kelurahan seririt tahun 2021. *RSUD Kota Semarang*. 2021;3:103–11.
67. Sargowo D. Gagal jantung kiri dan hipertensi pulmonal. *J Islam Med*. 2017;1(1):9–21.
68. Sammut MA, Condliffe R, Elliot C, Hameed A, Lewis R, Kiely DG, et al. Atrial flutter and fibrillation in patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension in the ASPIRE registry: comparison of rate versus rhythm control approaches. *Int J Cardiol [Internet]*. 2023;371(1):363–70.
69. Narechania S, Torbic H, Tonelli AR. Treatment discontinuation or interruption in pulmonary arterial hypertension. *J Cardiovasc Pharmacol Ther*. 2020;25(2):131–41.
70. Kondo T, Okumura N, Adachi S, Murohara T. Pulmonary hypertension: diagnosis, management, and treatment. *Nagoya J Med Sci*. 2019;81(1):19–30.
71. *Jornal Brasileiro de Pneumologia*. Risk factors pulmonary hypertension association [Internet]. *Alzheimer Society*. 2018 [dikutip 1 Februari 2023]. 1.
72. Dahlan M. Besar sampel dalam penelitian kedokteran dan kesehatan. 4 ed. Jakarta: *Epidemiologi Indonesia*; 2016. 46–60.
73. Chatterjee K, Goyal A, Boye B, Ranagswami J. 30-Day readmissions after pulmonary artery hypertension-related hospitalizations: measures and predictors. *Chest*. 2017;152(4):1.
74. Sastroasmoro, Ismael. *Dasar dasar metodologi penelitian klinis*. 2011. 45.
75. Care D, Suppl SS. Classification and diagnosis of diabetes: standards of medical care in diabetes 2018. *Diabetes Care*. 2018;41(1):13–27.
76. Cindy. *Anemia dan perempuan*. Rumah Sakit St. Carolus. 2023. hal. 1.
77. Kemenkes. *Pedoman nasional pelayanan kedokteran tata laksana pneumonia dewasa*. Kementerian Kesehat RI. 2021;4(1):12.
78. World Health Organization. *The Asia – Pacific perspective: redefining obesity and its treatment*. Sydney: Health Communications Australia; 2000. 17–8.
79. P2PTM Kemenkes RI. *Klasifikasi hipertensi*. Kementerian Kesehatan RI. 2018. 1.
80. Duffels MGJ, Engelfriet PM, Berger RMF, Loon RLE Van, Hoendermis E. Pulmonary arterial hypertension in congenital heart disease: an epidemiologic perspective from a Dutch Registry. *Int J Kardiol*. 2007;120(2):198–204.
81. Dinarti LK, Hartopo AB, Kusuma AD, Satwiko MG. The congenital heart disease in adult and pulmonary hypertension (COHARD-PH) registry : a descriptive study from single- center hospital registry of adult congenital heart disease and pulmonary hypertension in Indonesia. *BMC Cardiovasc Disord*. 2020;20(163):1–11.
82. Hurdman J, Condliffe R, Elliot CA, Davies C, Hill C, Wild JM. ASPIRE registry : assessing the spectrum of pulmonary hypertension identified at a referral centre. *Eur Respir J*. 2012;39(4):945–55.
83. Gall H, Felix JF, Schneck FK, Milger K, Sommer N, Voswinckel R, et al. The giessen pulmonary hypertension registry : survival in pulmonary

- hypertension subgroups. *J Hear Lung Transplant*. 2017;36(9):1–10.
84. Ling Y, Johnson MK, Kiely DG, Condliffe R, Elliot CA, Gibbs JSR, et al. Changing demographics , epidemiology, and survival of incident pulmonary arterial hypertension. *Am J Respir Crit Care Med*. 2012;186(8):790–6.
  85. DesJardin JT, Kolaitis NA, Kime N, Kronmal RA, Benza RL, Elwing JM, et al. Age-related differences in hemodynamics and functional status in pulmonary arterial hypertension: baseline results from the Pulmonary Hypertension Association Registry. *J Hear Lung Transplant*. 2020;39(9):945–53.
  86. Van Der Feen DE, Bartelds B, De Boer RA, Berger RMF. Pulmonary arterial hypertension in congenital heart disease: translational opportunities to study the reversibility of pulmonary vascular disease. *Eur Heart J*. 2017;38(26):2034–40.
  87. D’Alto M, Mahadevan VS. Pulmonary arterial hypertension associated with congenital heart disease. *Eur Respir Rev*. 2012;21(126):328–37.
  88. Morrell NW. Pulmonary hypertension due to BMPR2 mutation: a new paradigm for tissue remodeling? *Proc Am Thorac Soc*. 2006;3(8):1–6.
  89. Wright AF, Ewart M ann, Mair K, Nilsen M, Dempsie Y, Loughlin L, et al. Oestrogen receptor alpha in pulmonary hypertension. *European Soc Cardiol*. 2015;106(2):206–16.
  90. Hakiki G, Supriyanto S. Profil perempuan Indonesia 2018. Statistik BP, editor. Indonesia: Kementri Pemberdaya Perempuan dan Perlindungan Anak; 2018. 3–100 hal.
  91. Damayanti R. Status pekerjaan utama penduduk Indonesia per Agustus 2023 [Internet]. Badan Pusat Statistik. 2023 [dikutip 20 Januari 2024]. 1.
  92. Min J, Feng R, Badesch D, Berman-Rosenzweig E, Burger C, Chakinala M, et al. Obesity in pulmonary arterial hypertension the pulmonary hypertension association registry. *Ann Am Thorac Soc*. 2021;18(2):229–37.
  93. Irwin DC, Garat C V, Jr TC, Maclean PS, Sullivan TM, Erickson PF, et al. Obesity-related pulmonary arterial hypertension in rats correlates with increased circulating inflammatory cytokines and lipids and with oxidant damage in the arterial wall but not with hypoxia. *Pulm Circ*. 2014;4(4):1–15.
  94. Thienemann F, Dzudie A, Mocumbi AO, Blauwet L, Sani MU, Karaye KM, et al. The causes, treatment, and outcome of pulmonary hypertension in Africa: Insights from the Pan African Pulmonary Hypertension Cohort (PAPUCO) Registry. *Int J Cardiol*. 2016;221:1–7.
  95. Provencher S, Chemla D, Hervé P, Sitbon O, Humbert M, Simonneau G. Heart rate responses during the 6-minute walk test in pulmonary arterial hypertension. *Eur Respir J*. 2006;27(1):114–20.
  96. Hall JE. Guyton and hall textbook of medical physiology. 13 ed. Elsevier; 2015. 275.
  97. Ramani G, Lam D, Park M. The impact of anemia on survival in pulmonary arterial hypertension. *Hear Lung Transplant*. 2014;33(4):1–2.
  98. Hall JE. Guyton and hall textbook of medical physiology. 12 ed. Jackson: Elsevier; 2011. 6.
  99. Sonnweber T, Pizzini A, Tancevski I, Löffler J, Günter R. Anaemia , iron homeostasis and pulmonary hypertension : a review *European Society of Cardiology. Intern Emerg Med*. 2020;15(4):573–85.

100. Harbaum L, Baaske KM, Simon M, Oqueka T, Sinning C, Glatzel A, et al. Exploratory analysis of the neutrophil to lymphocyte ratio in patients with pulmonary arterial hypertension. *BMC Pulm Med*. 2017;17(1):1–9.
101. Rodwell VW, Bender DA, Botham KM, Weil PA. Harper's illustrated biochemistry. 30 ed. McGraw Hill Education, editor. 2015. 700 hal.
102. Shah SJ, Thenappan T, Rich S, Tian L, Archer SL, Gomberg-Maitland M. Association of serum creatinine with abnormal hemodynamics and mortality in pulmonary arterial hypertension. *Circulation*. 2008;117(19):1–10.
103. Sun H xiao, Li G ju, Du Z hui, Bing Z, Ji Z xian, Luo G, et al. The relationship between endothelial progenitor cells and pulmonary arterial hypertension in children with congenital heart disease. *BMC Pediatr*. 2019;19(502):1–6.
104. Chazova IY, Martynyuk T V., Valieva ZS, Gratsianskaya SY, Aleevskaya AM, Zorin A V., et al. Clinical and instrumental characteristics of newly diagnosed patients with various forms of pulmonary hypertension according to the Russian National Registry. *Biomed Res Int*. 2020;2020:1–12.
105. Li X ye, Zheng Y, Long Y, Zhang X, Zhang L, Tian D, et al. Effect of iloprost on biomarkers in patients with congenital pulmonary arterial hypertension. *Clin Exp Pharmacol Physiol*. 2017;44(9):914–23.
106. Canavan N. Rehospitalization is driving costs in pulmonary arterial hypertension. *Am Heal Drug Benefits*. 2013;6(9):1–2.
107. Burke JP, Hunsche E, Régulier E, Nagao M, Buzinec P, Drake W. Characterizing pulmonary hypertension-related hospitalization costs among Medicare Advantage or commercially insured patients with pulmonary arterial hypertension: a retrospective database study. *Am J Manag Care*. 2015;21(3):47–58.
108. Page SEE. Associations between short or long length of stay and 30-day readmission and mortality in hospitalized patients with heart failure. *JACC Hear Fail*. 2017;5(8):1–11.
109. Anand V, Roy SS, Archer SL, Weir EK, Garg SK, Duval S, et al. Trends and outcomes of pulmonary arterial hypertension-related hospitalizations in the United States: analysis of the nationwide inpatient sample database from 2001 through 2012. *JAMA Cardiol*. 2016;1(9):1021–9.
110. Burger CD, Long PK, Shah MR, McGoon MD, Miller DP, Romero AJ, et al. Characterization of first-time hospitalizations in patients with newly diagnosed pulmonary arterial hypertension in the REVEAL Registry. *Chest*. 2014;146(5):1263–73.
111. Tonelli AR, Arelli V, Minai OA, Newman J, Bair N, Heresi GA, et al. Causes and circumstances of death in pulmonary arterial hypertension. *Am J Respir Crit Care Med*. 2013;188(3):365–9.
112. Rush B, Biagioni BJ, Berger L, McDermid R. Mechanical ventilation outcomes in patients with pulmonary hypertension in the United States: a national retrospective cohort analysis. *J Intensive Care Med*. 2017;32(10):1–5.
113. Garcia MVF, Souza R, Caruso P. Predictors of invasive mechanical ventilation use in patients with acute decompensated pulmonary hypertension admitted to the intensive care unit. *ERJ Open Res*. 2023;9(2):1–4.

114. Yasuda K, Adachi S, Nishiyama I, Yoshida M, Nakano Y, Murohara T. Inhaled iloprost induces long-term beneficial hemodynamic changes in patients with pulmonary arterial hypertension receiving combination therapy. *Pulm Circ.* 2022;12(2):1–11.
115. Olschewski H. Inhaled iloprost for the treatment of pulmonary hypertension. *Eur Respir Rev.* 2009;18(111):29–34.
116. Lim YI, Low TINGING, Chan SIEWANG, Teo TINGWEI, Ao JIN, Jang JU, et al. Pulmonary arterial hypertension in a multi-ethnic asian population : characteristics , survival and mortality predictors from a 14-year follow-up study. *Respirology.* 2019;24(2):1–8.
117. Lilyasari O, Subekti Y, Atika N, Dinarti LK, Putri S, Opitasari C. Economic evaluation of sildenafil for the treatment of pulmonary arterial hypertension in Indonesia. *BMC Health Serv Res.* 2019;19(573):1–9.
118. Lewis KL. Sildenafil citrate therapy for pulmonary arterial hypertension. *Yearb Pulm Dis.* 2007;354(109):1–3.
119. Campo A, Mathai SC, Le Pavec J, Zaiman AL, Hummers LK, Boyce D, et al. Outcomes of hospitalisation for right heart failure in pulmonary arterial hypertension. *Eur Respir J.* 2011;38(2):359–67.
120. Jin Q, Chen D, Zhang X, Zhang F, Zhong D, Lin D, et al. Medical management of pulmonary arterial hypertension: current approaches and investigational drugs. *Pharmaceutics.* 2023;15(6):1–24.
121. Tsapenko M V, Comfere TBO, Mour GK, Mankad S V. Arterial pulmonary hypertension in noncardiac intensive care unit. *Mayo Clin.* 2008;4(5):1–18.
122. Stein PD, Matta F, Hughes PG. Scope of problem of pulmonary arterial hypertension. *Am J Med.* 2015;128(8):844–51.
123. Nuche J, Perez-Olivares C, Cal T, Lopez-Guarch C, Ynsaurriaga F, Escribano-Subias P. Clinical course of COVID-19 in pulmonary arterial hypertension patients. *Sci Lett.* 2020;73(9):775–8.
124. Tilea I, Varga A, Georgescu AM, Grigorescu BL. Critical care management of decompensated right heart failure in pulmonary arterial hypertension patients - an ongoing approach. *J Crit Care Med.* 2020;7(3):170–83.
125. Rao SD, Adusumalli S, Mazurek JA. Pulmonary hypertension in heart failure patients. *Card Fail Rev.* 2020;6(5):1–7.
126. Rosenkranz S, Gibbs JSR, Wachter R, Marco T De, Vonk-noordegraaf A, Vachie J luc. Clinical update Left ventricular heart failure and pulmonary. *Eur Heart J.* 2016;37:1–8.
127. Manuscript A, Hypertension P. Heart failure and pulmonary hypertension. *Hear Fail Clin.* 2011;6(2):215–22.
128. Sonnweber T, Nairz M, Theurl I, Petzer V, Tymoszyk P, Haschka D, et al. The crucial impact of iron deficiency definition for the course of precapillary pulmonary hypertension. *PLoS One.* 2018;13(8):1–17.
129. Quatredeni M, Mendes-ferreira P, Santos-ribeiro D, Nakhleh MK, Ghigna MR, Cohen-kaminsky S, et al. Iron deficiency in pulmonary arterial hypertension: a deep dive into the mechanisms. *Cells.* 2021;10(2):1–22.
130. Harder EM, Small AM, Fares WH. Primary cardiac hospitalizations in pulmonary arterial hypertension: trends and outcomes from 2001 to 2014. *Respir Med.* 2020;161:1–7.
131. Todd NW, Lavania S, Park MH, Iacono AT, Franks TJ, Galvin JR, et al.



- Variable prevalence of pulmonary hypertension in patients with advanced interstitial pneumonia. *J Hear Lung Transplant*. 2010;29(2):188–94.
132. Naranjo M, Lo KB, Mezue K, Rangaswami J. Effects of pulmonary hypertension and right ventricular function in short and long-term kidney function. *Curr Cardiol Rev*. 2019;15(1):3–11.
  133. Badlam JB, Badesch DB, Austin ED, Benza RL, Chung WK, Farber HW, et al. United states pulmonary hypertension scientific registry: baseline characteristics. *Chest*. 2021;159(1):1–16.
  134. Itelman E, Segel MJ, Kuperstein R, Feinberg M, Segev A, Segal G, et al. Pulmonary hypertension is associated with systemic arterial hypertension among patients with normal left ventricular diastolic function. *J Am Heart Assoc*. 2021;10(24):1–23.
  135. Olsson KM, Nickel NP, Tongers J, Hoepfer MM. Atrial flutter and fibrillation in patients with pulmonary hypertension. *Int jounal Cardiol*. 2013;167(5):1–6.
  136. Wanamaker B, Cascino T, Mclaughlin V, Oral H, Latchamsetty R, Siontis KC. Clinical arrhythmias atrial arrhythmias in pulmonary hypertension : pathogenesis, prognosis and management clinical arrhythmias. *Arrhythmia Electrophysiol Rev*. 2018;7(1):1–5.
  137. Cirulis MM, Ryan JJ, Archer SL. Pathophysiology, incidence, management, and consequences of cardiac arrhythmia in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. *Pulm Circ*. 2019;9(1):1–15.
  138. Cirulis MM, Ryan JJ, Archer SL. Pathophysiology, incidence, management, and consequences of cardiac arrhythmia in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. *Pulm Circ*. 2019;9(1):1–15.
  139. Grady D, Weiss M, Hernandez-Sanchez J, Pepke-Zaba J. Medication and patient factors associated with adherence to pulmonary hypertension targeted therapies. *Pulm Circ*. 2018;8(1):1–9.
  140. Pieper PG, Hoendermis ES. Pregnancy in women with pulmonary hypertension. *Netherlands Hear J*. 2011;19(12):1–4.
  141. Olsson KM, Channick R. Pregnancy in pulmonary arterial hypertension. *Eur Respir Rev*. 2016;25(142):1–7.